IGALMI
Live / Registered — Registered (as of 12 Nov 2024)
What this means for you
Registered since 12 Nov 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90295383
- Registration number
- 7565627
- Mark type
- Stylized text
- Filed
- 03 Nov 2020
- Published for opposition
- 18 May 2021
- Registered
- 12 Nov 2024
- Attorney of record
- BRENDAN J HUGHES
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment of agitation, namely, an orally-dissolving formulation used for the treatment of agitation associated with central nervous system disorders, namely, schizophrenia and bipolar disorder
Owner
- Bioxcel Therapeutics, Inc., New Haven, CT, US
- Bioxcel Therapeutics, Inc., New Haven, CT, US
- Bioxcel Therapeutics, Inc., New Haven, CT, US
Prosecution history
- 12 Nov 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 12 Nov 2024 — REGISTERED-PRINCIPAL REGISTER
- 08 Oct 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 08 Oct 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Aug 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 26 Jun 2024 — USE AMENDMENT FILED
- 22 Aug 2024 — SOU EXTENSION 5 GRANTED
- 26 Jun 2024 — SOU EXTENSION 5 FILED
- 21 Aug 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 26 Jun 2024 — TEAS STATEMENT OF USE RECEIVED
- 26 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Dec 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2023 — SOU EXTENSION 4 GRANTED
- 19 Dec 2023 — SOU EXTENSION 4 FILED